Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia

Recent Patents on CNS Drug Discovery

Volumn 5, Issue 1, 2010, Pages 23-34

  Kanuma, Kosuke ^a   Aoki, Takeshi ^a   Shimazaki, Youichi ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

G protein coupled receptor (GPCR); Metabotropic glutamate (mGlu) 5 receptor; Positive allosteric modulator; Potentiator; Schizophrenia

Indexed keywords

(4 FLUOROPHENYL) [3 [3 (4 FLUOROPHENYL) 1,2,4 OXADIAZOL 5 YL]PIPERIDIN 1 YL]METHANONE; 2 CHLORO 5 HYDROXYPHENYLGLYCINE; 3 CYANO N (1,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; 4 PHENYLETHYNYLBENZAMIDE; ADX 47273; ADX 63365; BIS(3 FLUOROBENZYLIDENE)HYDRAZINE; DIZOCILPINE; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; KETAMINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; PHENYLPIPERAZINE DERIVATIVE; QUISQUALIC ACID; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR STIMULATING AGENT; METABOTROPIC RECEPTOR;

ALLOSTERISM; BINDING SITE; COGNITION; COGNITIVE DEFECT; DRUG ACTIVITY; DRUG BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; PATENT; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; METABOLISM;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID AGONISTS; GLUTAMIC ACID; HUMANS; MODELS, BIOLOGICAL; PATENTS AS TOPIC; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 77449137160     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488910789753512     Document Type: Review

References (65)

1. Meltzer HY. Treatment of schizophrenia and spectrum disorders: Pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol Psychiatry 1999; 46(10): 1321-1327.
2. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51(3): 199-214.
3. Halberstadt AL. The phencyclidine-glutamate model of schizophrenia. Clin Neuropharmacol 1995; 18(3): 237-249.
4. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148(10): 1301-1308.
5. Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000; 23(3): 223-239.
6. Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: Focus on schizophrenia. Trends Neurosci 2001; 24(9): 527-533.
7. Deutch AY, Tam SY, Freeman AS, Bowers MB Jr, Roth RH. Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. Eur J Pharmacol 1987; 34(3): 257-264.
8. Verma A, Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 1996; 16(1): 373-379 (Pubitemid 26010723)
9. Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathology and new treatments of schizophrenia. Schizophr Bull 1998; 24: 285-301.
10. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology 2001; 156(2-3): 117-154. (Pubitemid 32702206)
11. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17(8): 2921-2927. (Pubitemid 27155025)
12. Pin JP, Duvoisin R. The metabotropic glutamate receptors: Structure and functions. Neuropharmacology 1995; 34(1): 1-26.
13. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Ann Rev Pharmacol Toxicol 1997; 37: 205-237. (Pubitemid 27238875)
14. O'Hara PJ, Sheppard PO, Thøgersen H, et al. The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins. Neuron 1993; 11(1): 41-52. (Pubitemid 23222532)
15. 2+-sensing receptor from bovine parathyroid. Nature 1993; 366(6455): 575-580.
16. Bargmann CI. Olfactory receptors, vomeronasal receptors, and the organization of olfactory information. Cell 1997; 90(4): 585-587.
17. Kaupmann K, Huggel K, Heid J, et al. Expression cloning of GABAB receptors uncovers similarity to metabotropic glutamate receptors. Nature 1997; 386(6622): 239-246. (Pubitemid 27142503)
18. Aniksztejn L, Bregestovski P, Ben-Ari Y. Selective activation of quisqualate metabotropic receptor potentiates NMDA but not AMPA responses. Eur J Pharmacol 1991; 205(2): 327-328.
19. Doherty AJ, Palmer MJ, Henley JM, Collingridge GL, Jane DE. (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacol 1997; 36(2): 265-267.
20. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 2000; 20(21): 7871-7879.
21. Kelso SR, Nelson TE, Leonard JP. Protein kinase C-mediated enhancement of NMDA currents by metabotropic glutamate receptors in Xenopus oocytes. J Physiol 1992; 449: 705-718.
22. Fitzjohn SM, Irving AJ, Palmer MJ, Harvey J, Lodge D, Collingridge GL. Activation of group I mGluRs potentiates NMDA responses in rat hippocampal slices. Neurosci Lett 1996; 203(3): 211-213. (Pubitemid 26040212)
23. Pisani A, Calabresi P, Centonze D, Bernardi G. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol 1997; 120(6): 1007-1014. (Pubitemid 27122637)
24. Skeberdis VA, Lan J, Opitz T, Zheng X, Bennett MV, Zukin RS. mGluR1-mediated potentiation of NMDA receptors involves a rise in intracellular calcium and activation of protein kinase C. Neuropharmacology 2001; 40(7): 856-865. (Pubitemid 32510799)
25. Aoki T, Narita M, Shibasaki M, Suzuki T. Metabotropic glutamate receptor 5 localized in the limbic forebrain is critical for the development of morphine-induced rewarding effect in mice. Eur J Neurosci 2004; 20(6): 1633-1638. (Pubitemid 39274046)
26. 2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 1992; 356(6369): 521-523.
27. Lan JY, Skeberdis VA, Jover T, et al. Protein kinase C modulates NMDA receptor trafficking and gating. Nat Neurosci 2001; 4(4): 382-390. (Pubitemid 32260114)
28. Lu YM, Jia Z, Janus C, et al. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 1997; 17(13): 5196-5205. (Pubitemid 27263833)
29. Jia Z, Lu Y, Henderson J, et al. Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn Mem 1998; 5(4-5): 331-343. (Pubitemid 29115263)
30. Chan MH, Chiu PH, Sou JH, Chen HH. Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice. Psychopharmacology 2008; 198(1): 141-148.
31. Balschun D, Zuschratter W, Wetzel W. Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory. Neuroscience 2006; 142(3): 691-702. (Pubitemid 44485913)
32. Darrah JM, Stefani MR, Moghaddam B. Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav Pharmacol 2008; 19(3): 225-234. (Pubitemid 351670403)
33. Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002; 43(8): 1199-1209. (Pubitemid 36084431)
34. Kinney GG, Burno M, Campbell UC, et al. Metabotropic glutamate subtype 5 receptor modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 2003; 306(1): 116-123. (Pubitemid 36734364)
35. Brody SA, Dulawa SC, Conquet F Geyer MA. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry 2004; 9(1): 35-41.
36. Knoflach F, Mutel V, Jolidon S, et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci USA 2001; 98(23): 13402-13407. (Pubitemid 33051375)
37. Christopoulos A. Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. Nat Rev Drug Discov 2002; 1(3): 198-210. (Pubitemid 37361423)
38. O'Brien JA, Lemaire W, Chen TB, et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol 2003; 64(3): 731-740. (Pubitemid 37048578)
39. O'Brien JA, Lemaire W Wittmann M, et al. A novel selective allosteric modulator potentiate the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther 2004; 309(2): 568-577.
40. Zhao Z, Wisnoski DD, O'Brien JA, et al. Challenges in the development of mGluR5 positive allosteric modulators: The discovery of CPPHA. Bioorg Med Chem Lett 2007; 17(5): 1386-1391. (Pubitemid 46240838)
41. Lindsley CW, Wisnoski DD, Leister WH, et al. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem 2004; 47(24):5825-5828.
42. Kinney GG, O'Brien JA, Lemaire W, et al. A novel seclective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 2005; 313(1): 199-206.
43. Epping-Jordan MP, Nayak S, Derouet F, et al. in vivo Characterization of mGluR5 positive allosteric modulators as novel treatments for schizophrenia and cognitive dysfunction. Neuropharmacology 2005; 49(Suppl): 243.
44. de Paulis T, Hemstapat K, Chen Y, et al. Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl) benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J Med Chem 2006; 49(11): 3332-3344.
45. Liu F, Grauer S, Kelley C, et al. ADX47273 [(S)-1-(4-fluorophenyl)-{3- (3-4-fluorophenyl)-[1,2,4]oxadiazol-5-yl)piperidin-1-yl}-methanone]: A novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther 2008; 327(3): 827-839.
46. Duggan, M.E., Lindsley, C.W., Wisnoski, D.D.: WO2004087048 (2004).
47. Lindsley, C.W., Wisnoski, D.D.: WO2005030128 (2005).
48. Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 2007; 62(7): 739-746. (Pubitemid 47374648)
49. Bessis, A-S., Bonnet, B., Le Poul, E., Rocher, J-P., Epping-Jordan, M.: WO2005044797 (2005).
50. Gagliardi, S., Palombi, G., Rocher, J-P.: WO2006048771 (2006).
51. Bugada, P., Gagliardi, S., Palombi, G., Rocher, J-P.: WO2006123244 (2006).
52. Bugada, P., Gagliardi, S., Le Poul, E., Mutel, V., Palombi, G., Rocher, J-P. : WO2006123249 (2006).
53. Farina, M., Gagliardi, S., Le Poul, E., Mutel, V., Palombi, G., Poli, S. M., Rocher, J-P.: WO2006123255 (2006).
54. Gagliardi, S., Le Poul, E., Lingard, L., Palombi, G., Poli, S. M., Rocher, J-P. : WO2006123257 (2006).
55. Farina, M., Gagliardi, S., Le Poul, E., Palombi, G., Rocher, J-P.: WO2006129199 (2006).
56. Le Poul, E., Palombi, G., Rocher, J-P.: WO2008056259 (2008).
57. Parsons, C. G. R., Jirgensons, A., Jaunzeme, I., Kalvinsh, I., Henrich, M., Vanejevs, M., Weil, T., Kauss, V., Danysz, W., Jatzke, C.: WO2007023245 (2005).
58. Parsons, C. G. R., Jirgensons, A., Jaunzeme, I., Kalvinsh, I., Henrich, M., Vanejevs, M., Weil, T., Kauss, V., Danysz, W., Jatzke, C.: WO2007023290 (2007).
59. Vanejevs M, Jatzke C, Renner S, et al. Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem 2008; 51(3): 634-647. (Pubitemid 351252291)
60. Engers DW, Rodriguez AL, Williams R, et al. Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273. ChemMedChem 2009; 4(4): 505-511.
61. Conn, P. J., Lindsley, C. W., Weaver, C. D., Rodriguez, A. L., Niswender, C. M., Jones, C. K., Williams, R.: WO2008151184 (2008).
62. Slassi, A., Isaac, M., Arora, J., Brown, D. G.: WO2007087135 (2007).
63. Arora, J., Isaac, M., Slassi, A., Edwards, L., Nair, S., Ma, F.: WO2008112440 (2008).
64. Gianotti, M., Lovell, P. J., Seri, C., Tehan, B. G.: WO2008152089 (2008).
65. Artioli, A., Lovell, P. J.: WO2008152090 (2008).